Drug Discovery@nature.com 14 December 2012

Advertisement Reichert is making it easier to have an SPR system installed in your lab today with this $4000 offer! FREE Startup FREE Training FREE Fluidics Kit. A $4000 value. Purchase any SPR system and receive free on-site setup and training. Reichert SPR systems are ultra-sensitive and cost-effective for all biomolecular interaction analysis. Visit website for details. ReichertSPR.com TABLE OF CONTENTS 14 December 2012 News Analysis Research Highlights Research & Reviews Careers Nature Reviews Drug Discovery is on Twitter Advertisement Nature and Nature Reviews Cancer COLLECTION ON CANCER METABOLISM This joint Collection from Nature and Nature Reviews Cancer highlights recent progress in the field and the promise of therapeutics based on interfering with metabolic pathways. Access the Web Focus at: www.nature.com/focus/cancermetabolism Papers in the reprint collection are freely available thanks to sponsorship from Teva Pharmaceuticals   News Top FDA under pressure to relax drug rules doi:10.1038/492019a Industry says antibiotic pipeline is being blocked by overly stringent clinical-trial requirements for new treatments. Full Text Gene therapies advance, but some see manufacturing challenges doi:10.1038/nm1212-1718 With more gene therapies expected to enter the market, experts say that manufacturing these deserves more attention to ensure that companies can meet demand — and do so safely. Full Text Computer program aims to rank vaccine development decisions doi:10.1038/nm1212-1720 A mathematical model may be able to help aligning the competing priorities of all stakeholders involved in vaccine development. Full Text Select-agent status could slow development of anti-SARS therapies doi:10.1038/nm1212-1722 The US government has brought in a new reclassification of the bioterrorism risk posed by SARS, which may hamper efforts at novel medical strategies. Full Text Analysis Top A current affair in MS doi:10.1038/scibx.2012.1223 Researchers have used the diabetes drug glibenclamide to block inflammation-induced neurodegeneration in mice. The team plans to test this in an investigator-led clinical trial in multiple sclerosis and is looking for pharma partners. Full Text Factors influencing non-approval of new drugs in Europe doi:10.1038/nrd3894 This analysis looked at marketing applications at the EMA for new active substances, revealing the extent to which certain underlying factors were associated with failure to be approved. Full Text Research Highlights Top Drug screening: A MuSIC-al way to identify drug pairs doi:10.1038/nrd3898 Researchers have a new method to identify synergistic drug pairs and new targets for the potential treatment of HIV. The method could be applicable to other therapeutic areas where combinations of drugs might offer improved benefits. Full Text Analgesics: Deadly snake venom for pain relief? doi:10.1038/nrd3897 Proteins from snake venom function as potent painkillers with a novel mechanism of action. They could be useful tools for dissecting pain pathways, as well as having potential therapeutic value themselves. Full Text Neurodegenerative diseases: Novel route to neuroprotection doi:10.1038/nrd3899 Compounds from a series based on P7C3 — an aminopropyl carbazole with neurogenic properties — have therapeutic effects in animal models of Parkinson's disease and amyotrophic lateral sclerosis. Full Text Research & Reviews Top Protein kinase C, an elusive therapeutic target? doi:10.1038/nrd3871 This Review looks at the efforts, challenges and opportunities for the protein kinase C family, which have been a major focus of drug discovery efforts. Full Text Tankyrase-targeted therapeutics: expanding opportunities in the PARP family doi:10.1038/nrd3868 This Review focuses on the biology of tankyrases and the discovery of tankyrase-specific inhibitors. It also considers the challenges that lie ahead for the clinical development of PARP family inhibitors in general. Full Text Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease–like pathology and cognitive decline doi:10.1038/nm.2965 New research shows that inhibition of IL-12 and IL-23 signaling reduces plaque load and improves cognitive deficits in mouse models of Alzheimer's disease. The researchers suggest that this pathway may be targeted therapeutically. Full Text Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis doi:10.1038/nbt.2434 Researchers have shown that microparticles bearing encephalitogenic peptides induce long-term T-cell tolerance in mice with relapsing experimental autoimmune encephalomyelitis, preventing the onset and modifying the course of the disease. Full Text JOBS of the week Key Postdoctoral Position at Wits Advanced Drug Delivery Platform Available Immediately University of the Witwatersrand, Johannesburg, South Africa Research Assistant II - Drug Delivery and Bioengineering The Wyss Institute for Biologically Inspired Engineering Drug Discovery Opportunities at D. E. Shaw Research D. E. Shaw Research Assistant / Associate Professor- Chemical Biology / Medicinal Chemistry / Drug Discovery Wayne State University Associate Professor in Drug Discovery (fixed-term) The University of Nottingham More Science jobs from EVENT 4th Annual World Drug Delivery & Formulation Summit 2013 18.-20.02.13 Berlin, Germany More science events from Careers Top Career snapshots archive Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field. Full Text Top Advertisement SciBX: Science-Business eXchange is a weekly publication that identifies and analyzes the most important translational research articles from over 40 journals. Find out which papers have real scientific and commercial potential, and why. Recommend SciBX to your library today.   Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant) For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our customer feedback department Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.